

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-3. (canceled).



4. (currently amended) The compound ~~according to Claim 1~~ which is:

N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.

5. (currently amended) The TFA salt according to Claim ~~1~~ 4 which is:














N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.

6. (currently amended) The compound ~~according to Claim 1~~ which is
selected from:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

7. (currently amended) The TFA salt according to Claim 4 which is selected from:



or a stereoisomer thereof.

8. (canceled).

9. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

10. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 6.

11-14. (canceled).

15. (currently amended) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 4.

16. (currently amended) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 6.

17-25. (canceled).